Published in Future Med Chem on July 01, 2013
Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development. Int J Parasitol Drugs Drug Resist (2015) 0.80
Purine import into malaria parasites as a target for antimalarial drug development. Ann N Y Acad Sci (2014) 0.78
Substrate and Inhibitor Specificity of the Plasmodium berghei Equilibrative Nucleoside Transporter Type 1. Mol Pharmacol (2016) 0.75
Pinpointing dynamic coupling in enzymes for efficient drug design. Future Sci OA (2016) 0.75
Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 37.89
The genome sequence of the malaria mosquito Anopheles gambiae. Science (2002) 20.36
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell (2000) 10.72
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
Qinghaosu (artemisinin): the price of success. Science (2008) 8.25
A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION. Am J Med (1964) 7.97
Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science (1967) 7.75
Physiological concentrations of purines and pyrimidines. Mol Cell Biochem (1994) 6.95
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A (1988) 5.92
Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet (1975) 5.15
Qinghaosu (artemisinin): an antimalarial drug from China. Science (1985) 4.95
Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet (2002) 4.13
Biochemistry of Plasmodium (malarial parasites). Microbiol Rev (1979) 3.86
Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol (1997) 3.66
Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (1997) 3.61
Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS Med (2011) 3.42
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem (1994) 3.34
On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A (1996) 3.29
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol (2003) 3.20
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science (1986) 3.06
Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate. Science (1977) 2.88
Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther (1998) 2.53
Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S A (2006) 2.43
Drugs for preventing malaria in travellers. Cochrane Database Syst Rev (2009) 2.29
Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry (2004) 2.24
Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science (1991) 2.15
Transition state analogues for enzyme catalysis. Nature (1969) 2.13
The crystal structure of GMP synthetase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. Nat Struct Biol (1996) 2.11
Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc Natl Acad Sci U S A (2004) 2.05
The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res (2000) 2.01
Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe (2009) 2.00
One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry (1998) 1.99
Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol (2001) 1.90
Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem (1999) 1.78
Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med (1995) 1.75
Hemoglobin degradation. Curr Top Microbiol Immunol (2005) 1.73
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother (2006) 1.72
A bifunctional thymidylate synthetase-dihydrofolate reductase in protozoa. Mol Biochem Parasitol (1984) 1.71
Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata. Proc Natl Acad Sci U S A (1980) 1.71
Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci (2011) 1.70
Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol (2005) 1.64
Enzymatic transition state theory and transition state analogue design. J Biol Chem (2007) 1.60
Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther (2000) 1.57
The 2.0 A structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor. Nat Struct Biol (1999) 1.57
History of human parasitology. Clin Microbiol Rev (2002) 1.56
Analysis of sequences from the extremely A + T-rich genome of Plasmodium falciparum. Gene (1987) 1.52
Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiol Rev (2005) 1.48
Dihydrofolate reductase from pyrimethamine-resistant Plasmodium berghei. J Biol Chem (1970) 1.48
Enzymatic transition states and transition state analog design. Annu Rev Biochem (1998) 1.48
Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum. Mol Pharmacol (1987) 1.46
An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency. N Engl J Med (1968) 1.45
Antimalarial drug discovery: old and new approaches. J Exp Biol (2003) 1.41
Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem (2007) 1.38
Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. Parasitology (2005) 1.35
Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect (2002) 1.35
Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J Biol Chem (2004) 1.34
Enzymatic transition states and transition state analogues. Curr Opin Struct Biol (2005) 1.29
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase. J Med Chem (2009) 1.29
Four generations of transition-state analogues for human purine nucleoside phosphorylase. Proc Natl Acad Sci U S A (2010) 1.28
Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem (2003) 1.27
Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase. Biochemistry (2009) 1.26
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother (2008) 1.26
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A (2012) 1.26
Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases. Nat Struct Biol (1999) 1.25
Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase. J Biol Chem (2001) 1.24
Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol Microbiol (2007) 1.21
Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii. J Biol Chem (2004) 1.21
Adenylosuccinate lyase deficiency. Mol Genet Metab (2006) 1.20
Regulation, genetics, and properties of adenylosuccinate synthetase: a review. Curr Top Cell Regul (1983) 1.18
Inhibition of maturation of human precursor lymphocytes by coformycin, an inhibitor of the enzyme adenosine deaminase. J Exp Med (1976) 1.15
Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr Drug Targets (2007) 1.14
Catalysis and sulfa drug resistance in dihydropteroate synthase. Science (2012) 1.14
A pre-transition-state mimic of an enzyme: X-ray structure of adenosine deaminase with bound 1-deazaadenosine and zinc-activated water. Biochemistry (1993) 1.14
Transition state analogue discrimination by related purine nucleoside phosphorylases. J Am Chem Soc (2006) 1.13
Quinoline antimalarials: mechanisms of action and resistance. Int J Parasitol (1997) 1.13
Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases. J Am Chem Soc (2009) 1.11
Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal model. PLoS One (2011) 1.10
Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum. J Biol Chem (2008) 1.06
Intrinsic activity and stability of bifunctional human UMP synthase and its two separate catalytic domains, orotate phosphoribosyltransferase and orotidine-5'-phosphate decarboxylase. J Biol Chem (1996) 1.05
Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase. Biochemistry (1995) 1.04
Transition state structure of Salmonella typhimurium orotate phosphoribosyltransferase. Biochemistry (1996) 1.03
The 2.0 A structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor. Biochemistry (1999) 1.02
Synthesis of 5'-methylthio coformycins: specific inhibitors for malarial adenosine deaminase. J Am Chem Soc (2007) 1.02
Mizoribine and mycophenolate mofetil. Curr Med Chem (1999) 1.02
An atypical orthologue of 6-pyruvoyltetrahydropterin synthase can provide the missing link in the folate biosynthesis pathway of malaria parasites. Mol Microbiol (2007) 1.01
In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism. Antimicrob Agents Chemother (1990) 1.01
Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J Med Chem (1999) 1.01
Transition states and inhibitors of the purine nucleoside phosphorylase family. Curr Top Med Chem (2005) 1.00
Inborn errors of the purine nucleotide cycle: adenylosuccinase deficiency. J Inherit Metab Dis (1997) 0.99
Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J Mol Biol (2003) 0.99
Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am J Hum Genet (1997) 0.98
Kinetic mechanism of human hypoxanthine-guanine phosphoribosyltransferase: rapid phosphoribosyl transfer chemistry. Biochemistry (1997) 0.97
Structure of coformycin, an unusual nucleoside of microbial origin. J Am Chem Soc (1974) 0.96
Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases. Biochemistry (2009) 0.95
A novel enzyme complex of orotate phosphoribosyltransferase and orotidine 5'-monophosphate decarboxylase in human malaria parasite Plasmodium falciparum: physical association, kinetics, and inhibition characterization. Biochemistry (2005) 0.95
Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo. Adv Exp Med Biol (1984) 0.94
Purine and pyrimidine pathways as targets in Plasmodium falciparum. Curr Top Med Chem (2011) 0.93
The biochemistry of sirtuins. Annu Rev Biochem (2006) 4.32
Enzymatic transition states and dynamic motion in barrier crossing. Nat Chem Biol (2009) 2.30
Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry (2004) 2.24
Structural insights into intermediate steps in the Sir2 deacetylation reaction. Structure (2008) 2.12
Atomic detail of chemical transformation at the transition state of an enzymatic reaction. Proc Natl Acad Sci U S A (2008) 2.01
Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry (2003) 1.83
Femtomolar transition state analogue inhibitors of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli. J Biol Chem (2005) 1.76
Transition state structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues. Biochemistry (2005) 1.73
Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell (2005) 1.71
Ribocation transition state capture and rebound in human purine nucleoside phosphorylase. Chem Biol (2009) 1.55
Neighboring group participation in the transition state of human purine nucleoside phosphorylase. Biochemistry (2007) 1.53
A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem (2007) 1.47
Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem (2003) 1.46
Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase. Biophys J (2008) 1.46
Femtosecond dynamics coupled to chemical barrier crossing in a Born-Oppenheimer enzyme. Proc Natl Acad Sci U S A (2011) 1.46
Transition state analogs of 5'-methylthioadenosine nucleosidase disrupt quorum sensing. Nat Chem Biol (2009) 1.39
Picomolar inhibitors as transition-state probes of 5'-methylthioadenosine nucleosidases. ACS Chem Biol (2007) 1.37
Picomolar transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-A. Biochemistry (2004) 1.35
Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J Biol Chem (2004) 1.34
Promoting vibrations in human purine nucleoside phosphorylase. A molecular dynamics and hybrid quantum mechanical/molecular mechanical study. J Am Chem Soc (2004) 1.32
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase. J Med Chem (2009) 1.29
Energetic mapping of transition state analogue interactions with human and Plasmodium falciparum purine nucleoside phosphorylases. J Biol Chem (2005) 1.28
Four generations of transition-state analogues for human purine nucleoside phosphorylase. Proc Natl Acad Sci U S A (2010) 1.28
Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem (2003) 1.27
Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase. Biochemistry (2009) 1.26
Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function. J Biol Chem (2004) 1.26
Structural rationale for the affinity of pico- and femtomolar transition state analogues of Escherichia coli 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase. J Biol Chem (2005) 1.26
Transition-state structure of human 5'-methylthioadenosine phosphorylase. J Am Chem Soc (2006) 1.25
Second generation transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase. J Med Chem (2005) 1.25
Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J Biol Chem (2001) 1.25
Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase. J Biol Chem (2001) 1.24
Transition State Structure for the Hydrolysis of NAD Catalyzed by Diphtheria Toxin. J Am Chem Soc (1997) 1.20
Detecting ricin: sensitive luminescent assay for ricin A-chain ribosome depurination kinetics. Anal Chem (2009) 1.19
Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the Mannich reaction. Org Lett (2003) 1.18
Mass-dependent bond vibrational dynamics influence catalysis by HIV-1 protease. J Am Chem Soc (2011) 1.18
Altered thermodynamics from remote mutations altering human toward bovine purine nucleoside phosphorylase. Biochemistry (2008) 1.18
Binding equilibrium isotope effects for glucose at the catalytic domain of human brain hexokinase. J Am Chem Soc (2003) 1.17
SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. Curr Med Chem (2004) 1.17
Transition state analogues in structures of ricin and saporin ribosome-inactivating proteins. Proc Natl Acad Sci U S A (2009) 1.15
Transition-state analysis of S. pneumoniae 5'-methylthioadenosine nucleosidase. J Am Chem Soc (2007) 1.15
Insight into catalytically relevant correlated motions in human purine nucleoside phosphorylase. J Phys Chem A (2006) 1.14
Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase. J Biol Chem (2010) 1.14
Remote mutations alter transition-state structure of human purine nucleoside phosphorylase. Biochemistry (2008) 1.13
Transition state analogue discrimination by related purine nucleoside phosphorylases. J Am Chem Soc (2006) 1.13
Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases. J Am Chem Soc (2009) 1.11
Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal model. PLoS One (2011) 1.10
Conformational dynamics in human purine nucleoside phosphorylase with reactants and transition-state analogues. J Phys Chem B (2010) 1.07
Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum. J Biol Chem (2008) 1.06
Acyclic ribooxacarbenium ion mimics as transition state analogues of human and malarial purine nucleoside phosphorylases. J Am Chem Soc (2007) 1.06
Structure and inhibition of a quorum sensing target from Streptococcus pneumoniae. Biochemistry (2006) 1.06
Activating the phosphate nucleophile at the catalytic site of purine nucleoside phosphorylase: a vibrational spectroscopic study. J Am Chem Soc (2004) 1.04
Protein mass-modulated effects in the catalytic mechanism of dihydrofolate reductase: beyond promoting vibrations. J Am Chem Soc (2014) 1.04
Transition state structure for ADP-ribosylation of eukaryotic elongation factor 2 catalyzed by diphtheria toxin. Biochemistry (2004) 1.04
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J Med Chem (2003) 1.04
Targeting the polyamine pathway with transition-state analogue inhibitors of 5'-methylthioadenosine phosphorylase. J Med Chem (2004) 1.03
A picomolar transition state analogue inhibitor of MTAN as a specific antibiotic for Helicobacter pylori. Biochemistry (2012) 1.02
Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry (2002) 1.02
Synthesis of 5'-methylthio coformycins: specific inhibitors for malarial adenosine deaminase. J Am Chem Soc (2007) 1.02
Plasmodium falciparum purine nucleoside phosphorylase is critical for viability of malaria parasites. J Biol Chem (2008) 1.01
Transition Path Sampling Study of the Reaction Catalyzed by Purine Nucleoside Phosphorylase. Z Phys Chem (N F) (2008) 1.01
Transport of purines and purine salvage pathway inhibitors by the Plasmodium falciparum equilibrative nucleoside transporter PfENT1. Mol Biochem Parasitol (2009) 1.01
Nucleophilic participation in the transition state for human thymidine phosphorylase. J Am Chem Soc (2004) 1.00
Transition states and inhibitors of the purine nucleoside phosphorylase family. Curr Top Med Chem (2005) 1.00
Loop-tryptophan human purine nucleoside phosphorylase reveals submillisecond protein dynamics. Biochemistry (2009) 0.99
Inhibition of ricin A-chain with pyrrolidine mimics of the oxacarbenium ion transition state. Biochemistry (2004) 0.98
Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry (2008) 0.98
Transition-state variation in human, bovine, and Plasmodium falciparum adenosine deaminases. J Am Chem Soc (2007) 0.98
Transition-state interactions revealed in purine nucleoside phosphorylase by binding isotope effects. J Am Chem Soc (2008) 0.97
Ionic states of substrates and transition state analogues at the catalytic sites of N-ribosyltransferases. Biochemistry (2003) 0.97
Tryptophan-free human PNP reveals catalytic site interactions. Biochemistry (2008) 0.96
L-Enantiomers of transition state analogue inhibitors bound to human purine nucleoside phosphorylase. J Am Chem Soc (2007) 0.95
Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases. Biochemistry (2009) 0.95
Transition-state structure of neisseria meningitides 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase. J Am Chem Soc (2007) 0.95
Ricin A-chain substrate specificity in RNA, DNA, and hybrid stem-loop structures. Biochemistry (2004) 0.94
Circular DNA and DNA/RNA hybrid molecules as scaffolds for ricin inhibitor design. J Am Chem Soc (2007) 0.94
Azetidine based transition state analogue inhibitors of N-ribosyl hydrolases and phosphorylases. J Med Chem (2008) 0.94
Over-the-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase. Biochemistry (2003) 0.93
Purine and pyrimidine pathways as targets in Plasmodium falciparum. Curr Top Med Chem (2011) 0.93
Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases. Org Biomol Chem (2006) 0.92
Inhibition and structure of Trichomonas vaginalis purine nucleoside phosphorylase with picomolar transition state analogues. Biochemistry (2007) 0.92
Binding causes the remote [5'-3H]thymidine kinetic isotope effect in human thymidine phosphorylase. J Am Chem Soc (2004) 0.91
Femtomolar inhibitors bind to 5'-methylthioadenosine nucleosidases with favorable enthalpy and entropy. Biochemistry (2012) 0.91
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases. J Med Chem (2003) 0.91
Second-sphere amino acids contribute to transition-state structure in bovine purine nucleoside phosphorylase. Biochemistry (2008) 0.91
Effect of dietary p-aminobenzoic acid on murine Plasmodium yoelii infection. J Infect Dis (2003) 0.90
Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states. J Am Chem Soc (2004) 0.90
Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein. Biochemistry (2009) 0.90
Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett (2008) 0.90
Conformational states of human purine nucleoside phosphorylase at rest, at work, and with transition state analogues. Biochemistry (2010) 0.90
Transition state analysis of thymidine hydrolysis by human thymidine phosphorylase. J Am Chem Soc (2010) 0.89
Entropy-driven binding of picomolar transition state analogue inhibitors to human 5'-methylthioadenosine phosphorylase. Biochemistry (2011) 0.89
Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase. Biochemistry (2002) 0.89
Anopheles gambiae purine nucleoside phosphorylase: catalysis, structure, and inhibition. Biochemistry (2007) 0.89
Design and synthesis of potent "sulfur-free" transition state analogue inhibitors of 5'-methylthioadenosine nucleosidase and 5'-methylthioadenosine phosphorylase. J Med Chem (2010) 0.89
Ground-state destabilization in orotate phosphoribosyltransferases by binding isotope effects. Biochemistry (2011) 0.88
Isotope effect-mapping of the ionization of glucose demonstrates unusual charge sharing. J Am Chem Soc (2003) 0.88
Methylthioinosine phosphorylase from Pseudomonas aeruginosa. Structure and annotation of a novel enzyme in quorum sensing. Biochemistry (2011) 0.88
Ricin A-chain activity on stem-loop and unstructured DNA substrates. Biochemistry (2005) 0.87
Characterizing DNA methyltransferases with an ultrasensitive luciferase-linked continuous assay. Anal Chem (2011) 0.87
Pyrophosphate activation in hypoxanthine--guanine phosphoribosyltransferase with transition state analogue. Biochemistry (2010) 0.86